Maintenance Therapy for CD20+ Indolent Lymphoma: Who Should Receive Maintenance?
E Koo, DA Macdonald - Canadian …, 2024 - canadianhematologytoday.com
Maintenance rituximab (MR) has been a mainstay of treatment in Canada for CD20‑positive
indolent lymphoma for two decades. The adoption of MR into clinical practice occurred after …
indolent lymphoma for two decades. The adoption of MR into clinical practice occurred after …